Fresenius Medical Care AG

Fresenius Medical Care announced BEACON-US, a comprehensive scientific research initiative to expand clinical and real-world evidence for high-volume hemodiafiltration (HVHDF) in U.S. dialysis patients. The company is expanding access to HVHDF across the U.S., building on two decades of international evidence supporting improved survival and reduced hospitalization. Early U.S. observations show strong clinical performance, including 40% fewer muscle cramps and improved dialysis adequacy, aligning with landmark studies like CONVINCE. CEO Helen Giza emphasized HVHDF's potential to transform kidney care and its role in the FME Reignite strategy.

Fresenius Medical Care AG announced the launch of a new share buyback program totaling up to EUR 1 billion. The program commenced on May 28, 2026, and is expected to conclude by May 27, 2027. The first tranche, valued at up to EUR 600 million, is scheduled to be completed by December 15, 2026. The repurchased shares will primarily be cancelled to reduce share capital, with a smaller portion allocated to incentive-based compensation plans.

Fresenius Medical Care held its Annual General Meeting, where shareholders approved a dividend of EUR 1.49 per share for fiscal year 2025. The company announced the successful completion of its €1.0 billion share buyback program, which repurchased 24.8 million shares, and granted a new authorization for future treasury share acquisitions. Following the AGM, the Management Board resolved to cancel 24,848,819 treasury shares, reducing the share capital by EUR 24,848,819.00. The company also highlighted strong financial performance in 2025, including 8% organic revenue growth and an increased operating margin of 11.3%, alongside the US FDA approval and ongoing commercial launch of its 5008X CAREsystem.

Fresenius Medical Care AG filed its Interim Report of Financial Condition and Results of Operations for the three months ended March 31, 2026 and 2025. The report details the company's financial performance and position, outlines its FME Reignite strategy with profitability aspirations for 2030, and highlights the FME25+ Program targeting €1.2 billion in sustainable savings by the end of 2027. It also discusses various risk factors, including the potential impact of the U.S. Supreme Court’s Loper Bright decision on regulatory interpretations and the influence of private payors.

Fresenius Medical Care reported strong adjusted operational and financial progress in Q1 2026, with organic revenue growth of 4% and adjusted operating income increasing 10% at constant currency. Adjusted EPS also rose 16%, benefiting from the completed EUR 1.0 billion share buyback program. However, reported operating income and net income declined significantly due to EUR 166 million in one-time costs related to the FME25+ transformation program. The company confirmed its full-year 2026 outlook for broadly flat revenue and mid-single digit operating income growth.